Hydrochlorothiazide and Risk of Skin Cancer

CompletedOBSERVATIONAL
Enrollment

2,953,748

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

March 5, 2021

Study Completion Date

March 5, 2021

Conditions
Non-melanoma Skin CancerMelanomaHypertension
Interventions
DRUG

Hydrochlorothiazide

Exposure to hydrochlorothiazide will be defined as a prescription for hydrochlorothiazide alone or in combination with non-ACE inhibitor antihypertensive drugs at cohort entry date.

DRUG

Angiotensin-converting enzyme (ACE) inhibitors

Exposure to ACE inhibitors will be defined as a prescription for an ACE inhibitor alone or in combination with non-hydrochlorothiazide antihypertensive drugs at cohort entry date.

Trial Locations (1)

H3T1E2

Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

Drug Safety and Effectiveness Network, Canada

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Canadian Network for Observational Drug Effect Studies, CNODES

OTHER

NCT04334824 - Hydrochlorothiazide and Risk of Skin Cancer | Biotech Hunter | Biotech Hunter